The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial
Open accessAbstract
Importance: The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective: To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Participants: Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. Overall, 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median (IQR) follow-up duration was 26.7 (17.2-33.5) months. Interventions: The chemotherapy regimens were fluorouracil continuous intravenous infusion at 5 g/m2 over 120 hours and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for 6 cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. Main Outcomes and Measures: The primary end point of the study was overall survival (OS). The secondary end point was progression-free survival (PFS) and safety. Results: Overall, 126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years). The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group. The study met its primary end point of improved OS (stratified hazard ratio [HR], 0.42; 95% CI, 0.23-0.77; P = .004) in favor of chemotherapy plus radiotherapy. Progression-free survival was also improved in the chemotherapy plus radiotherapy group compared with the chemotherapy-alone group (stratified HR, 0.36; 95% CI, 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms. The frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe grade 3 or higher hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group. Conclusions and Relevance: In this randomized clinical trial, radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive patients with mNPC. Trial Registration: ClinicalTrials.gov Identifier: NCT02111460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Gomez, D. R., Blumenschein, G. R., Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30532-0 · Cited by 1,086
Cited by
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12218 · Cited by 413
Self-citation
Metadata
- Authors
- You, R., Liu, Y.-P., Huang, P.-Y., Zou, X., Sun, R., He, Y.-X., Wu, Y.-S., Shen, G.-P., Zhang, H.-D., Duan, C.-Y., Tan, S. H., Cao, J.-Y., Li, J.-B., Xie, Y.-L., Zhang, Y.-N., Wang, Z.-Q., Yang, Q., Lin, M., Jiang, R., Zhang, M.-X., Hua, Y.-J., Tang, L.-Q., Zhuang, A.-H., Chen, Q.-Y., Guo, L., Mo, H.-Y., Chen, Y., Mai, H.-Q., Ling, L., Liu, Q., Chua, M. L. K., & Chen, M.-Y.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-09-01
- Volume
- 6
- Issue
- 9
- Pages
- 1345
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3045194380
- Cited by
- 251
- References
- 2
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2020.1808
- The paper
- You, R., Liu, Y.-P., Huang, P.-Y., Zou, X., Sun, R., He, Y.-X., Wu, Y.-S., Shen, G.-P., Zhang, H.-D., Duan, C.-Y., Tan, S. H., Cao, J.-Y., Li, J.-B., Xie, Y.-L., Zhang, Y.-N., Wang, Z.-Q., Yang, Q., Lin, M., Jiang, R., . . . Chen, M.-Y. (2020). Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.1808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.